Search results for "Viral Load"

showing 10 items of 232 documents

Oxidative Stress and Mitochondrial Impairment After Treatment with Anti-HIV Drugs: Clinical Implications

2011

Thirty years after the discovery of HIV infection, there are numerous antiretroviral drugs that control the disease when administered in a potent combination referred to as Highly Active Antiretroviral Therapy (HAART). This therapy reduces the viral load and improves immune system reconstitution, leading to a significant reduction of HIV-related morbidity and mortality. However, HAART does not completely eliminate HIV, so treatment must continue throughout the patient's life. Prolonged use of HAART has been related to long-term adverse events that can compromise patient health. These deleterious effects have been reported for the majority of antiretroviral drugs and are the most common caus…

Anti-HIV AgentsHIV InfectionsDiseasemedicine.disease_causeAntioxidantsImmune systemRisk FactorsAntiretroviral Therapy Highly ActiveDiabetes mellitusDrug DiscoveryAnimalsHumansMedicineAdverse effectPharmacologychemistry.chemical_classificationReactive oxygen speciesbusiness.industrymedicine.diseaseMitochondriaDiscontinuationOxidative StresschemistryImmunologyReactive Oxygen SpeciesbusinessViral loadOxidative stressCurrent Pharmaceutical Design
researchProduct

HCV genotype 5: an orphan virus

2013

HCV genotype 5 (HCV-5) is the least known HCV genotype. It is found mainly in South Africa and in restricted areas of Belgium, Spain, France, Syria and Greece. Sporadic cases are reported worldwide. The main modes of transmission are blood transfusion and iatrogenic causes. Little is known about its origin, but various studies have elucidated its spread worldwide. In endemic areas, patients infected with HCV-5 are on average older and have a higher viral load and more advanced fibrosis than those infected with non-HCV-5 genotypes. The current standard of care for HCV-5 chronic infection is 48 weeks of dual therapy with pegylated interferon plus ribavirin. ‘Favourable’ Il28B polymorphisms a…

Blood transfusionGenotypemedicine.medical_treatmentHepacivirusAntiviral Agentschemistry.chemical_compoundPegylated interferonGenotypemedicinePrevalenceHumansPharmacology (medical)PharmacologyTransmission (medicine)business.industryRibavirinvirus diseasesHepatitis Cmedicine.diseaseHepatitis Cdigestive system diseasesChronic infectionInfectious DiseasesTreatment OutcomechemistryImmunologyHost-Pathogen InteractionsbusinessViral loadmedicine.drug
researchProduct

First case in Italy of acquired resistance to oseltamivir in an immunocompromised patient with influenza A/H1N1v infection

2010

A pandemic influenza A/H1N1v strain with the neuraminidase H274Y mutation was detected in nasal secretions of a 2-year-old leukemic patient with influenza-like illness after 18 days of treatment with oseltamivir. At baseline, no drug-resistant virus was found, while 4 days after treatment initiation a mix- ture of wild-type and mutated virus was detected. After treatment interruption, the wild type influenza virus re-emerged and became prevalent in nasal secretions after a few days, suggesting the lower fitness of the mutated virus strain. The patient slowly improved concurrently with a decrease in virus load, which resulted negative 42 days after diagnosis. No other drug-resistant influenz…

Bodily SecretionsvirusesResistanceDrug ResistanceSettore MED/42 - Igiene Generale E Applicatamedicine.disease_causePandemic H1N1v Oseltamivir Resistancechemistry.chemical_compoundInfluenza A Virus H1N1 SubtypePandemicInfluenza A virusInfluenza A VirusViralChildViral LoadTreatment OutcomeInfectious DiseasesItalyChild PreschoolRNA ViralFemaleViral diseaseViral loadH1N1vSequence AnalysisH1N1v; Oseltamivir; Pandemic; Resistance; Amino Acid Substitution; Antiviral Agents; Bodily Secretions; Child Preschool; Female; Humans; Immunocompromised Host; Influenza A Virus H1N1 Subtype; Influenza Human; Italy; Molecular Sequence Data; Mutation Missense; Neuraminidase; Nose; Oseltamivir; RNA Viral; Sequence Analysis DNA; Treatment Outcome; Viral Load; Viral Proteins; Withholding Treatment; Drug Resistance Viral; Virology; Infectious DiseasesHumanOseltamivirMolecular Sequence DataMutation MissenseNeuraminidaseBiologyNoseAntiviral AgentsVirusresistanceImmunocompromised HostViral ProteinsOseltamivirVirologyDrug Resistance ViralInfluenza HumanmedicineHumansH1N1 SubtypePreschoolInfluenza-like illnessPandemicSequence Analysis DNADNAVirologyInfluenzaInfluenza; A/H1N1v; Oseltamivir; resistancechemistryAmino Acid SubstitutionWithholding TreatmentMutationbiology.proteinRNAA/H1N1vMissenseNeuraminidase
researchProduct

Prevalence of oral lesions in HIV patients related to CD4 cell count and viral load in a Venezuelan population

2006

Objetivo: Determinar la prevalencia de las lesiones bucales en un grupo de pacientes VIH+, su relación con el contaje de linfocitos CD4 y la carga viral, en una muestra de la población venezolana Materiales y métodos: En el presente estudio se evaluaron 75 pacientes adultos VIH+, provenientes del Centro para la Atención de Pacientes con Enfermedades Infectocontagiosas de la Facultad de Odontología de la Universidad Central de Venezuela. Cada uno de ellos fue examinado clínicamente para la detección de las lesiones presentes en la mucosa bucal. Igualmente se les determinó el contaje de células CD4+ mediante citometría de flujo, así como la carga viral mediante la técnica TR-RCP (Transcriptas…

CD4+stomatognathic diseasesVIH+oral lesionsUNESCO::CIENCIAS MÉDICASViral loadcarga viral:CIENCIAS MÉDICAS [UNESCO]HIV+lesiones bucales
researchProduct

TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1.

2011

Summary.  The triglycerides × glucose (TyG) index is a recently proposed surrogate marker of insulin resistance (IR), calculated from fasting plasma triglyceride and glucose concentrations. We tested the host and viral factors associated with Tyg and homeostasis model assessment (HOMA) scores, comparing their associations with histological features and with sustained virological response (SVR) in patients with genotype 1 chronic hepatitis C(G1CHC). Three hundred and forty consecutive patients with G1CHC were considered. All had a liver biopsy scored by one pathologist for staging and grading (Scheuer), and graded for steatosis, which was considered moderate–severe if ≥30%. Anthropometric an…

CHRONIC HEPATITIS CAdultBlood GlucoseMalemedicine.medical_specialtyAlpha interferonHepacivirusGastroenterologyAntiviral AgentsGLUCOSEBody Mass IndexPolyethylene GlycolsInsulin resistanceVirologyInternal medicineRibavirinmedicineHomeostasisHumansTriglyceridesAgedHepatologymedicine.diagnostic_testbusiness.industryFatty liverInterferon-alphaHepatitis CHepatitis C ChronicMiddle AgedViral Loadmedicine.diseaseRecombinant ProteinsFatty LiverInfectious DiseasesEndocrinologyTreatment OutcomeLiver biopsySUSTAINED VIROLOGICAL RESPONSERNA ViralDrug Therapy CombinationFemaleSteatosisInsulin ResistancebusinessViral loadBody mass indexJournal of viral hepatitis
researchProduct

Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepa…

2017

Summary Real-world studies are relevant to complement clinical trials on novel antiviral therapies against chronic hepatitis C; however, clinical practice data are currently limited. This study investigated effectiveness and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r)±dasabuvir (DSV)±ribavirin (RBV) for treatment of HCV genotype (GT) 1 and GT4 infection in a large real-world cohort. The German Hepatitis C Registry is an observational cohort study prospectively collecting clinical practice data on direct-acting antiviral therapies. Patients with GT1/4 infection treated with OBV/PTV/r±DSV±RBV were analysed. Effectiveness was assessed by sustained virologic response in 558 patients…

CyclopropanesLiver CirrhosisMaleHepacivirusSeverity of Illness IndexCohort Studieschemistry.chemical_compound0302 clinical medicine2-NaphthylamineGermanyMedicineAnilides030212 general & internal medicineSulfonamidesDasabuvirValineHepatitis CMiddle AgedViral LoadInfectious DiseasesTreatment Outcome030211 gastroenterology & hepatologyDrug Therapy CombinationFemalemedicine.drugAdultmedicine.medical_specialtyMacrocyclic CompoundsGenotypeProlineLactams Macrocyclic03 medical and health sciencesVirologyOmbitasvir/paritaprevir/ritonavirInternal medicineHumansUracilAgedRitonavirHepatologybusiness.industryHepatitis C Chronicmedicine.diseaseVirologyOmbitasvirDiscontinuationRegimenchemistryParitaprevirRitonavirCarbamatesbusinessJournal of viral hepatitis
researchProduct

Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A met…

2017

The direct-acting antiviral regimen of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) ± dasabuvir (DSV) ± ribavirin (RBV) demonstrated high rates of sustained viral response at post-treatment week 12 (SVR12) in clinical trials for treatment of hepatitis C virus (HCV) genotypes (GT) 1 and 4. To confirm the effectiveness of this regimen in the real world, we conducted meta-analyses of published literature on 30 April 2016. Freeman-Tukey transformation determined the SVR rate within GTs 1a, 1b, and 4, as well as specific SVR rates by cirrhosis or prior treatment experience status. Rates of virologic relapse, hepatic decompensation, drug discontinuation, and serious adverse events were also …

CyclopropanesLiver CirrhosisSustained Virologic ResponseHCV genotypes 1 and 4ComorbidityHepacivirusmedicine.disease_causeGastroenterologymeta-analysichemistry.chemical_compound0302 clinical medicineAnilides030212 general & internal medicineSulfonamidesDasabuvirValineHepatitis CViral LoadHepatitis Creal-world effectiveneInfectious DiseasesTreatment Outcome2D; 3D; HCV genotypes 1 and 4; hepatitis C; meta-analysis; real-world effectiveness; Hepatology; Infectious Diseases; Virology030211 gastroenterology & hepatologyDrug Therapy Combinationmedicine.drug3Dmedicine.medical_specialtyMacrocyclic CompoundsGenotypeProlineHepatitis C virusLactams MacrocyclicInfectious DiseaseAntiviral Agents03 medical and health sciencesInternal medicineVirologyRibavirinmedicineHumans2DRitonavirHepatologybusiness.industryRibavirinmedicine.diseaseOmbitasvirRegimenchemistryParitaprevirImmunologyRitonavirCarbamatesbusinessJournal of viral hepatitis
researchProduct

Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults

2015

Objective: The prevalence of overweight and obesity is increasing among HIV-infected patients. Whether standard antiretroviral drug dosage is adequate in heavy individuals remains unresolved. We assessed the virological and immunological responses to initial efavirenz (EFV)-containing regimens in heavy compared to normal-weight HIV-infected patients. Design: Observational European cohort collaboration study. Methods: Eligible patients were antiretroviral-naive with documented weight prior to EFV start and follow-up viral loads after treatment initiation. Cox regression analyses evaluated the association between weight and time to first undetectable viral load ( 50 copies/ml) after initial s…

CyclopropanesMaleEfavirenz; HIV; Immunological response; Virological response; Weight; Adult; Antiretroviral Therapy Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; Humans; Male; Middle Aged; Obesity; Regression Analysis; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Body WeightHIV InfectionsOverweight10234 Clinic for Infectious DiseasesCohort Studieschemistry.chemical_compoundAntiretroviral Therapy Highly ActiveImmunology and AllergyHIV InfectionImmunological responsevirus diseasesVirological responseMiddle AgedViral LoadReverse Transcriptase InhibitorTreatment OutcomeInfectious DiseasesAlkynesCohort2723 Immunology and AllergyRegression AnalysisReverse Transcriptase InhibitorsFemalemedicine.symptomViral loadCohort studyHumanBenzoxazineAdultmedicine.medical_specialtyEfavirenzImmunologyAntiretroviral Therapy610 Medicine & healthRegression AnalysiPharmacokineticsInternal medicinemedicineHumansHighly ActiveObesity2403 Immunologybusiness.industryProportional hazards modelBody WeightHIV2725 Infectious DiseasesEfavirenz; HIV; Immunological response; Virological response; Weight; Adult; Antiretroviral Therapy Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; Humans; Male; Middle Aged; Obesity; Regression Analysis; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Body Weight; Immunology and Allergy; Immunology; Infectious Diseasesmedicine.diseaseWeightObesityBenzoxazinesCD4 Lymphocyte Countlnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]chemistryImmunologyCohort StudieEfavirenzbusiness
researchProduct

Roflumilast inhibits respiratory syncytial virus infection in human differentiated bronchial epithelial cells.

2013

Respiratory syncytial virus (RSV) causes acute exacerbations in COPD and asthma. RSV infects bronchial epithelial cells (HBE) that trigger RSV associated lung pathology. This study explores whether the phosphodiesterase 4 (PDE4) inhibitor Roflumilast N-oxide (RNO), alters RSV infection of well-differentiated HBE (WD-HBE) in vitro. WD-HBE were RSV infected in the presence or absence of RNO (0.1-100 nM). Viral infection (staining of F and G proteins, nucleoprotein RNA level), mRNA of ICAM-1, ciliated cell markers (digital high speed videomicroscopy, β-tubulin immunofluorescence, Foxj1 and Dnai2 mRNA), Goblet cells (PAS), mRNA of MUC5AC and CLCA1, mRNA and protein level of IL-13, IL-6, IL-8, T…

CyclopropanesScienceAminopyridinesBronchiCell CountRespiratory Syncytial Virus InfectionsBiologyMucin 5ACImmunofluorescenceVirus ReplicationVirusAntioxidantsChloride ChannelsTubulinGene expressionmedicineHumansCiliaRNA MessengerRespiratory systemRoflumilastMessenger RNAMetaplasiaMultidisciplinarymedicine.diagnostic_testQRvirus diseasesCell DifferentiationEpithelial CellsForkhead Transcription FactorsAxonemal Dyneinsrespiratory systemViral LoadVirologyMolecular biologyRespiratory Syncytial VirusesOxidative StressViral replicationBenzamidesMedicineCytokinesTumor necrosis factor alphaGoblet CellsReactive Oxygen SpeciesBiomarkersmedicine.drugResearch ArticlePloS one
researchProduct

Long-term outcomes of oral rehabilitation with dental implants in HIV-positive patients: A retrospective case series

2016

Background: The existing information on oral rehabilitations with dental implants in VIH-positive patients is scarce and of poor quality. Moreover, no long-term follow-up studies are available. Hence, the aims of this study were to describe the long-term survival and success rates of dental implants in a group of HIV-positive patients and to identify the most common postoperative complications, including peri-implant diseases. Material and Methods: A retrospective case series of HIV-positive subjects treated with dental implants at the School of Dentistry of the University of Barcelona (Spain) was studied. Several clinical parameters were registered, including CD4 cell count, viral load and…

Dental Restoration FailurePeri-implantitismedicine.medical_treatmentAlveolar Bone LossMEDLINEDentistryHIV InfectionsOdontologíaComplications (Medicine)Malalties de la boca03 medical and health sciences0302 clinical medicineMucositismedicineHumansDental Restoration Failure030212 general & internal medicineGeneral DentistryRetrospective StudiesDental ImplantsRehabilitationImplants dentalsbusiness.industryResearchDental implantsRetrospective cohort study030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseasePeri-ImplantitisCiencias de la saludTreatment OutcomeComplicacions (Medicina)Mouth diseasesOtorhinolaryngologySpainUNESCO::CIENCIAS MÉDICASSurgeryImplantOral SurgeryHIV-positive personsbusinessPersones seropositivesViral loadFollow-Up Studies
researchProduct